Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar mania.

J Psychopharmacol · 2021 · PMC8366183 · PMID 33691517

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

Furthermore, there was a clear effect of region, with numerical or nominally significant differences in favor of brexpiprazole versus placebo in patients from the EU but not in those from the US.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.